Our findings differ from those studies showing a significant prognostic impact of CDKN2A deletion in both grade 3 and grade 4 IDHm astrocytomas, as detected by array-based techniques [7, 10]. This evidence concerns the gene CDKN2A and astrocytoma (excluding glioblastoma).